然而，据中国药物可及性中国研究小组介绍，降低专利药价格，提高药品可及性，在中国进展并不顺利。
However, according to Chinese medicines for introduction of Chinese research group, lower prices of patented drugs, to improve drug availability in China, progress is not smooth.
如果偏离此种立法精神，消弱专利制度的激励作用，将对药品可及性和不发达国家经济、制药行业产生负面影响。
If we departure this spirit, with the weakness of incentive effect, there would be some negative influences over drug accessibility and economic welfare and Pharmacy Industry.
通过比较研究的方法，对我国药品定价、补偿和可及性等问题提出一些政策建议。
This paper proposes some Suggestions to change policies in drug pricing, reimbursement and access in China by the comparative study.
葛兰素史克中国公司还将通过扩大生产、扩大药品价格下浮空间，让中国农村地区和城市一样，提高对葛兰素史克药品的可及性。
GSKCI will also increase access to its products in both city and rural areas of China through greater expansion of production and through price flexibility.
葛兰素史克中国公司还将通过扩大生产、扩大药品价格下浮空间，让中国农村地区和城市一样，提高对葛兰素史克药品的可及性。
GSKCI will also increase access to its products in both city and rural areas of China through greater expansion of production and through price flexibility.
应用推荐